undamentalytics Newsletter
Sign in

Recursion Pharmaceuticals, Inc. revenue

Recursion Pharmaceuticals, Inc.'s revenue was $74.7m in fiscal 2025, up 26.9% on the year before. Since fiscal 2019 ($2.3m) it has grown at a compound 78.4% a year. Over the last twelve months it was $68.2m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue24104045597568
Growth on the year before—+70.8%+156.9%+291.5%+11.9%+32.0%+26.9%—
Gross profit—410−8214420
Gross margin—100.0%100.0%−21.2%4.5%23.1%5.0%29.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses and services $74.3M 99.4% ▲ 27.0%
Grant $425,000 0.6% ▲ 21.1%
Geography
Region Revenue Share YoY
United States $39.3M 52.7% ▼ 31.4%
United Kingdom $35.3M 47.3% ▲ 3013.4%
Other Countries $0 0.0% ▼ 100.0%

From Recursion Pharmaceuticals, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Recursion Pharmaceuticals, Inc. $68.2m 56.2% 12.9%
Cytokinetics Inc $67.7m -21.1% 89.5%
Abcellera Biologics Inc. $66.2m 101.3% -23.0%
Wave Life Sciences, Inc. $70.9m 202.3% 20.7%
Viridian Therapeutics, Inc.\de $71.1m 23220.3% 264.4%
Clinuvel Pharmaceuticals Ltd $64.3m 5.2% —

Compare with peers

Head to head: CYTK vs RXRXABCL vs RXRXRXRX vs WVERXRX vs VRDN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Recursion Pharmaceuticals, Inc.